<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40173">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02583399</url>
  </required_header>
  <id_info>
    <org_study_id>CPI-CL-022</org_study_id>
    <nct_id>NCT02583399</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients</brief_title>
  <official_title>A Multi-Center, Open-Label Pharmacokinetic and Safety Study for Reduction in Fever or Management of Pain in Pediatric Subjects Aged Birth to Six Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cumberland Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cumberland Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the pharmacokinetic profile of a single
      dose of intravenous ibuprofen administered over approximately ten (10) minutes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate the pharmacokinetic profile of a single
      dose of intravenous ibuprofen administered over approximately ten (10) minutes.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the pharmacokinetic profile (Maximum Plasma Concentration [Cmax]) of a single dose of IVIb administered over 5-7 minutes.</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetic profile (Elimination Half Life [T 1/2]) of a single dose of IVIb administered over 5-7 minutes.</measure>
    <time_frame>4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of single dose of intravenous ibuprofen by assessing treatment emergent adverse events</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Pain</condition>
  <condition>Fever</condition>
  <arm_group>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibuprofen, 10 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Ibuprofen, 10 mg/kg</description>
    <arm_group_label>Ibuprofen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be a hospitalized male or female subject between birth (&gt; 37 weeks gestational age)
             and &lt; six (6) months of age.

          -  Have a clinical indication of pain or fever.

          -  Have written informed consent provided by legal parent, guardian, or authorized agent
             prior to participation in the study or performance of any study-only related
             procedures.

        Exclusion Criteria:

          -  Have inadequate intravenous access.

          -  Have an uncorrected ductus dependent congenital heart disease.

          -  Have any history of allergy or hypersensitivity to non-steroidal anti-inflammatory
             drug or aspirin.

          -  Have a current history of uncorrected hypovolemia or acute renal disease.

          -  Have a current history of acute liver disease.

          -  Have received NSAID, acetaminophen, or aspirin drug therapy within four hours prior
             to dosing. Have received another investigational drug within the past 30 days.

          -  Be otherwise unsuitable for the study, in the opinion of the Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd Rice, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Byron Kaelin</last_name>
    <phone>615-255-0068</phone>
    <phone_ext>250</phone_ext>
    <email>bkaelin@cumberlandpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jerry Fox</last_name>
    <phone>615-255-0068</phone>
    <phone_ext>226</phone_ext>
    <email>jfox@cumberlandpharma.com</email>
  </overall_contact_backup>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 9, 2017</lastchanged_date>
  <firstreceived_date>October 20, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric (Birth to less than 6 months of age)</keyword>
  <keyword>Pain</keyword>
  <keyword>Fever</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
